Market Place
Sourcing Support
APL Healthcare`s Unit-IV Classified As VAI By The USFDA
14 Mar 2026 //
INDPHARMAPOST
Aurobindo Pharma`s Dyrupeg Faces Health Canada Compliance Notice
09 Jan 2026 //
ECONOMICTIMES
FDA Issues Form 483 with 5 Observations to Aurobindo Unit
18 Dec 2025 //
ECONOMICTIMES
Aurobindo Pharma Receives 9 Observations From USFDA For Eugia
15 Nov 2025 //
INDPHARMAPOST
Fire at Subsidiary Temporarily Impact Aurobindo Pharma Production
19 Sep 2025 //
ECONOMICTIMES
Apitoria Pharma Gets 5 Observations from USFDA for API Plant
31 Aug 2025 //
INDPHARMAPOST
Aurobindo Pharma recalls 4,608 pain reliever bottles in US
27 Jun 2025 //
ECONOMICTIMES
USFDA issues Form 483 with 11 observations to Aurobindo Pharma
11 Apr 2025 //
ECONOMICTIMES
USFDA Inspects Aurobindo Pharma`s Warehouse in New Jersey
20 Feb 2025 //
BUSINESS STD
Aurobindo Pharma Ltd Falls 6.07%, BSE Healthcare index Drops 2.12%
19 Feb 2025 //
BUSINESS STD
Aurobindo Pharma Slips as Andhra Plant Gets 5 USFDA Observations
19 Feb 2025 //
BUSINESS STD
Aurobindo, Glenmark, Zydus Recall Products in US Over Manufacturing
15 Dec 2024 //
BUSINESS STD
U.S. FDA issues 10 observations to Aurobindo arm`s API unit
01 Oct 2024 //
THE HINDU
Aurobindo, Glenmark, FDC Recall US Products Over Manufacturing Issues
26 Aug 2024 //
ECONOMICTIMES
Aurobindo Pharma`s Eugia Unit-3 gets warning letter from USFDA, shares fall
16 Aug 2024 //
ECONOMICTIMES
FDA Issues `Official Action Indicated` For Aurobindo`s Eugia Unit
06 Aug 2024 //
BSEINDIA
Under FDA scrutiny, Aurobindo`s Eugia tallies a 5th Form 483 in less than a year
14 May 2024 //
FIERCE PHARMA
Aurobindo arm gets 3 observations from US FDA after Andhra unit inspection
08 Apr 2024 //
MONEYCONTROL
USFDA inspects Aurobindo Pharma`s New Jersey-based facility, issues 10 observations
24 Dec 2023 //
MONEY CONTROL
FDA classifies Aurobindo plant as needing `voluntary` action
20 Dec 2023 //
FIERCE PHARMA
Aurobindo`s Andhra plant receives 1 observation from USFDA after inspection
20 Sep 2023 //
ECONOMIC TIMES
Alembic, Aurobindo Pharma issue separate US drug recalls
21 Aug 2023 //
FIERCE PHARMA
Aurobindo’s Hyd unit gets 3 observations from USFDA
23 Jul 2023 //
TIMES OF INDIA
US. FDA issues Form 483 with four observations to Aurobindo Pharma
19 May 2023 //
THE HINDU
Aurobindo Pharma gets VAI classification from USFDA for Telangana plant
16 Feb 2023 //
ECONOMIC TIMES
Aurobindo Pharma arm gets 2 observations from USFDA
19 Jan 2023 //
BUSINESS STANDARD
QC violations raised by FDA at another Aurobindo site
08 Dec 2022 //
ENDPTS
Aurobindo Pharma gets EIR from USFDA for its Andhra Pradesh facility
17 Nov 2022 //
HEALTH ET
USFDA concludes inspection of Aurobindo Pharma`s unit XI
16 Nov 2022 //
LIVEMINT
Aurobindo units recall products in US market for manufacturing issues
08 Nov 2022 //
ECONOMIC TIMES
USFDA completes inspection at Aurobindo Pharma`s Unit VII in Hyderabad
05 Aug 2022 //
INDIAINFOLINE
Aurobindo Pharma AP unit gets 3 USFDA observations
03 Aug 2022 //
ET HEALTH
Aurobindo receives Form 483 from the FDA
13 May 2022 //
FIERCEPHARMA
Aurobindo, Sun Pharma recall products in US market for defaulting norms
28 Feb 2022 //
BUSINESS-STANDARD
Aurobindo Pharma gets warning letter from USFDA for API facility
15 Jan 2022 //
ECONOMIC TIMES
Aurobindo Pharma, Unichem recall products in US; amid manufacturing issues
07 Dec 2021 //
FREEPRESSJOURNAL
India`s Aurolife under water with the FDA after chronic leaks imperil generics
24 Nov 2020 //
FIERCE PHARMA
Indian drug firms recall various products in US market
13 Nov 2020 //
TRIBUNEINDIA
Aurobindo Pharma declines 6% on USFDA warning letter for Dayton facility
22 Oct 2020 //
BUSINESS-STANDARD
FDA issues Form 483 with 9 observations to Aurobindo Pharma`s USA facility
04 Jun 2020 //
MONEYCONTROL
Aurobindo Pharma`s US facility receives nine observations from US FDA
04 Jun 2020 //
PHARMABIZ
Aurobindo`s US manufacturing facility gets inspectional observations
03 Jun 2020 //
BUSINESS-STANDARD
Aurobindo Pharma gets VAI classification from USFDA for Hyderabad unit
20 Apr 2020 //
INDIATIMES
US FDA finds fault with standards at Aurobindo`s oral solids facility
04 Feb 2020 //
IN-PHARMATECHNOLOGIST
USFDA cautions Aurobindo`s oral solids formulation facility of regulatory action
29 Jan 2020 //
MONEYCONTROL
Aurobindo Pharma recalls Mirtazapine tablets in US over label error
03 Jan 2020 //
BUSINESS-STANDARD
AuroMedics Pharma recalls over 59000 vials of antipsychotic injection in US
13 Dec 2019 //
BUSINESS-STANDARD
USFDA finds several violations in Aurobindo sterile injections unit
23 Nov 2019 //
THE ECONOMIC TIMES
Aurobindo Pharma`s Hyderabad facility gets 14 observations from US FDA
14 Nov 2019 //
PHARMABIZ
Glenmark recalls over 2 lakh cartons of product in US
12 Nov 2019 //
THE ECONOMIC TIMES
Indian pharma firms receive 34% of FDA warnings this year
21 Aug 2019 //
DOWNEARTH
NDEA & NDMA Impurities: Another Indian Manuf. Receives an FDA Warning Letter
13 Aug 2019 //
RAPS
Rising OAIs bring spotlight back on regulatory compliance at Indian pharma
21 May 2019 //
MONEYCONTROL
FDA designates Aurobindo`s 3 facilities as `Official Action Indicated`
18 May 2019 //
BUSINESS-STANDARD
Aurobindo Pharma falls 6% after USFDA classifies inspection as OAI
17 May 2019 //
BUSINESS-STANDARD
Aurobindo Pharma falls 6% as USFDA classified inspection as OAI
16 May 2019 //
MONEYCONTROL
Hair in one vail, Aurobindo recalls 88k Lidocaine injections from US
18 Apr 2019 //
ECONOMIC TIMES
Aurobindo gets FDA thrashing at yet another sterile drug plant
10 Apr 2019 //
FIERCE PHARMA
Aurobindo Pharma Gets 11 Observations From U.S. FDA For Its Telangana Plant
13 Mar 2019 //
BLOOMBERGQUINT
Aurobindo facility receives Form 483 over procedural issues
05 Mar 2019 //
IN-PHARMATECHNOLOGIST
